|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-8-31
|
|
pubmed:abstractText |
To examine the efficacy and safety of short courses of azithromycin and ofloxacin for treating multidrug-resistant (MDR, i.e., resistant to chloramphenicol, ampicillin, and cotrimoxazole) and nalidixic acid-resistant enteric fever, azithromycin (1 g once daily for 5 days at 20 mg/kg/day) and ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day) were compared in an open randomized study in adults admitted to a hospital with uncomplicated enteric fever. A total of 88 blood culture-confirmed patients were enrolled in the study (86 with Salmonella enterica serovar Typhi and 2 with S. enterica serovar Paratyphi A). Of these, 44 received azithromycin and 44 ofloxacin. A total of 68 of 87 (78%) isolates were MDR serovar Typhi, and 46 of 87 (53%) were nalidixic acid resistant. The MIC(90) (range) of azithromycin was 8 (4 to 16) microgram/ml for the isolates. The MIC(90) (range) of ofloxacin for the nalidixic acid-sensitive isolates was 0.03 (0.015 to 0.06) microgram/ml and for the nalidixic acid-resistant isolates it was 0.5 (0.25 to 1.0) microgram/ml. There was no significant difference in the overall clinical cure rate with ofloxacin and azithromycin (38 of 44 [86.4%] versus 42 of 44 [95.5%]; P = 0.27) or in the patients infected with nalidixic acid-resistant typhoid (17 of 21 [81.0%] versus 24 of 25 [96.0%]; P = 0.16). However, patients with nalidixic acid-resistant typhoid treated with ofloxacin had a longer fever clearance time compared with those treated with azithromycin (174 [60 to 264] versus 135 [72 to 186] h; P = 0.004) and had positive fecal cultures after the end of treatment (7 of 17 [41%] versus 0 of 19 [0%]; P = 0.002). Both antibiotics were well tolerated. A 5-day course of azithromycin was effective for the treatment of enteric fever due to MDR and nalidixic-acid-resistant serovar Typhi, whereas the ofloxacin regimen chosen was less satisfactory for these strains.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-10223698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-10334265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-10348767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-10473232,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-2154435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-2154441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-7475749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-7810998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-7911192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-7928825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-7986000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8385094,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8396080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8645805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8707358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8737139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8913468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-8994789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9231214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9269277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9431387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9620400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9643778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10858343-9652619
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1855-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10858343-Adolescent,
pubmed-meshheading:10858343-Adult,
pubmed-meshheading:10858343-Anti-Bacterial Agents,
pubmed-meshheading:10858343-Anti-Infective Agents,
pubmed-meshheading:10858343-Azithromycin,
pubmed-meshheading:10858343-Drug Resistance, Multiple,
pubmed-meshheading:10858343-Female,
pubmed-meshheading:10858343-Humans,
pubmed-meshheading:10858343-Male,
pubmed-meshheading:10858343-Nalidixic Acid,
pubmed-meshheading:10858343-Ofloxacin,
pubmed-meshheading:10858343-Outcome Assessment (Health Care),
pubmed-meshheading:10858343-Pilot Projects,
pubmed-meshheading:10858343-Typhoid Fever
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
